309 related articles for article (PubMed ID: 33392619)
1. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
Ochi M; Murakami Y; Nishibuchi I; Kubo K; Imano N; Takeuchi Y; Kimura T; Hamai Y; Emi M; Okada M; Nagata Y
J Radiat Res; 2021 Jan; 62(1):142-148. PubMed ID: 33392619
[TBL] [Abstract][Full Text] [Related]
2. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
3. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
4. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
5. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system.
Miyoshi S; Nishibuchi I; Murakami Y; Katsuta T; Imano N; Hirokawa J; Hamai Y; Emi M; Okada M; Nagata Y
Int J Clin Oncol; 2023 Mar; 28(3):382-391. PubMed ID: 36646953
[TBL] [Abstract][Full Text] [Related]
7. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.
Habu T; Kumanishi R; Ogata T; Fujisawa T; Mishima S; Kotani D; Kadowaki S; Nakamura M; Hojo H; Fujiwara H; Kumagai S; Koyama S; Fujita T; Kinoshita T; Nishikawa H; Yano T; Tajika M; Muro K; Mitsunaga S; Kojima T; Bando H
Esophagus; 2023 Jul; 20(3):533-540. PubMed ID: 36750480
[TBL] [Abstract][Full Text] [Related]
8. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
[TBL] [Abstract][Full Text] [Related]
9. Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement.
Chung TR; Kim JH; Lee IJ; Cho Y; Kim JW; Lee CG; Jung DH; Park JJ; Youn YH; Park H
Dig Liver Dis; 2019 Nov; 51(11):1610-1616. PubMed ID: 31175014
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
[TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study.
Pape M; Vissers PAJ; de Vos-Geelen J; Hulshof MCCM; Gisbertz SS; Jeene PM; van Laarhoven HWM; Verhoeven RHA
Cancer Sci; 2022 Mar; 113(3):1038-1046. PubMed ID: 34986523
[TBL] [Abstract][Full Text] [Related]
14. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Makiuchi T; Nagumo R; Kitagawa Y
Ann Surg Oncol; 2020 Feb; 27(2):460-467. PubMed ID: 31376034
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy.
Ego M; Abe S; Nakatani Y; Nonaka S; Suzuki H; Yoshinaga S; Oda I; Kato K; Honma Y; Itami J; Daiko H; Saito Y; Boku N
Surg Endosc; 2021 Apr; 35(4):1766-1776. PubMed ID: 32356109
[TBL] [Abstract][Full Text] [Related]
16. Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.
Guo JC; Huang TC; Lin CC; Hsieh MS; Chang CH; Huang PM; Lee JM; Hsu FM; Chia-Hsien Cheng J; Wang HP; Yeh KH; Cheng AL; Hsu CH
J Thorac Oncol; 2015 Oct; 10(10):1481-9. PubMed ID: 26313683
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
[TBL] [Abstract][Full Text] [Related]
18. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
[TBL] [Abstract][Full Text] [Related]
20. Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Shih LH; Chen SW; Li SH
Sci Rep; 2018 Oct; 8(1):15073. PubMed ID: 30305678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
